TABLE 1.
Patient characteristics
| Patients treated at a single site | Patients transferred to another site for treatment | All patients | |
|---|---|---|---|
| Total no. of patients | 67 | 81 | 148 |
| ≥18 years ‐ <40 years | 35 (52.2%) | 23 (28.4%) | 58 (39.2%) |
| ≥40 years ‐ <50 years | 11 (16.4%) | 16 (19.8%) | 27 (18.2%) |
| ≥50 years ‐ <60 years | 9 (13.4%) | 18 (22.2%) | 27 (18.2%) |
| ≥60 years ‐ <70 years | 4 (6%) | 9 (11.1%) | 13 (8.8%) |
| ≥70 years ‐ <80 years | 4 (6%) | 12 (14.8%) | 16 (10.8%) |
| ≥80 years | 4 (6%) | 3 (3.7%) | 7 (4.7%) |
| No. pregnant | 3 (4.5%) | 3 (3.7%) | 6 (4.1%) |
| Laboratory values at presentation: | |||
| Platelet count, ×109/l, median (IQR) | 15 (10–27.5) | 11 (7–22) | 13 (8–24) |
| Hemoglobin, g/l, median (IQR) | 92 (83.5–108) | 94 (76–110) | 92 (80–110) |
| Creatinine, µmol/l, median (IQR) | 82 (69–108) | 101 (77–138) | 92 (70–129) |
| No. with schistocytes reported on first blood film: | 57 (85.1%) | 65 (80.2%) | 122 (82.4%) |
| No. with CNS signs or symptoms in first 48 h: | 28 (41.8%) | 51 (63%) | 79 (53.4%) |
| No. with troponin raised above ULN: | 42 (62.7%) | 60 (74.1%) | 102 (68.9%) |
| Mortality at 30 days: | 12 (17.9%) | 6 (7.4%) | 18 (12.2%) |
| Length of stay in days for patients surviving to discharge, median (IQR): | 12 (8–21) | 15 (10–25.5) | 14 (9–22) |
Abbreviations: CNS, central nervous system; IQR, interquartile range; PEX, plasma exchange; ULN, upper limit of normal.